Tecan Group AG (0QLN.L)
CHF 162.88
(3.52%)
CHF 162.88
(3.52%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 183.12 Million CHF | -6.68% |
| 2022 | 196.24 Million CHF | 1.86% |
| 2021 | 192.65 Million CHF | 275.59% |
| 2020 | -109.71 Million CHF | 49.76% |
| 2019 | -218.39 Million CHF | 24.59% |
| 2018 | -289.61 Million CHF | 0.89% |
| 2017 | -292.21 Million CHF | -24.5% |
| 2016 | -234.7 Million CHF | -18.07% |
| 2015 | -198.79 Million CHF | -62.01% |
| 2014 | -122.7 Million CHF | 14.47% |
| 2013 | -143.46 Million CHF | -1.51% |
| 2012 | -141.33 Million CHF | 12.05% |
| 2011 | -160.7 Million CHF | -45.27% |
| 2010 | -110.62 Million CHF | -118.58% |
| 2009 | -50.6 Million CHF | -51.87% |
| 2008 | -33.32 Million CHF | 33.25% |
| 2007 | -49.92 Million CHF | -70.11% |
| 2006 | -29.34 Million CHF | -188.7% |
| 2005 | 33.08 Million CHF | 207.87% |
| 2004 | -30.67 Million CHF | -17.72% |
| 2003 | -26.05 Million CHF | 46.16% |
| 2002 | -48.39 Million CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 141.63 Million CHF | 0.0% |
| 2023 Q4 | 183.12 Million CHF | 0.0% |
| 2023 FY | 183.12 Million CHF | -6.68% |
| 2023 Q2 | 177.86 Million CHF | 0.0% |
| 2022 FY | 196.24 Million CHF | 1.86% |
| 2022 Q4 | 196.24 Million CHF | 0.0% |
| 2022 Q2 | 176.42 Million CHF | 0.0% |
| 2021 FY | 192.65 Million CHF | 275.59% |
| 2021 Q4 | 192.65 Million CHF | 0.0% |
| 2021 Q2 | -179.94 Million CHF | 0.0% |
| 2020 Q4 | -109.71 Million CHF | 0.0% |
| 2020 Q2 | -142.48 Million CHF | 0.0% |
| 2020 FY | -109.71 Million CHF | 49.76% |
| 2019 Q4 | -218.39 Million CHF | 0.0% |
| 2019 Q2 | -217.65 Million CHF | 0.0% |
| 2019 FY | -218.39 Million CHF | 24.59% |
| 2018 Q4 | -294.53 Million CHF | 0.0% |
| 2018 FY | -289.61 Million CHF | 0.89% |
| 2018 Q2 | -297.91 Million CHF | 0.0% |
| 2017 Q4 | -297.08 Million CHF | 0.0% |
| 2017 Q2 | -237.78 Million CHF | 0.0% |
| 2017 FY | -292.21 Million CHF | -24.5% |
| 2016 FY | -234.7 Million CHF | -18.07% |
| 2016 Q4 | -234.7 Million CHF | 0.0% |
| 2016 Q2 | -238.95 Million CHF | 0.0% |
| 2015 Q4 | -198.79 Million CHF | 0.0% |
| 2015 Q2 | -165.63 Million CHF | 0.0% |
| 2015 FY | -198.79 Million CHF | -62.01% |
| 2014 Q4 | -122.7 Million CHF | 0.0% |
| 2014 Q2 | -129.78 Million CHF | 0.0% |
| 2014 FY | -122.7 Million CHF | 14.47% |
| 2013 FY | -143.46 Million CHF | -1.51% |
| 2013 Q4 | -143.46 Million CHF | 0.0% |
| 2013 Q2 | -128.05 Million CHF | 0.0% |
| 2012 FY | -141.33 Million CHF | 12.05% |
| 2012 Q4 | -141.33 Million CHF | 0.0% |
| 2012 Q2 | -133.02 Million CHF | 0.0% |
| 2011 FY | -160.7 Million CHF | -45.27% |
| 2011 Q4 | -160.7 Million CHF | 0.0% |
| 2011 Q2 | -78.12 Million CHF | 0.0% |
| 2010 FY | -110.62 Million CHF | -118.58% |
| 2010 Q2 | -71.99 Million CHF | 0.0% |
| 2010 Q4 | -110.62 Million CHF | 0.0% |
| 2009 Q4 | -50.6 Million CHF | 0.0% |
| 2009 FY | -50.6 Million CHF | -51.87% |
| 2008 FY | -33.32 Million CHF | 33.25% |
| 2007 FY | -49.92 Million CHF | -70.11% |
| 2006 FY | -29.34 Million CHF | -188.7% |
| 2005 FY | 33.08 Million CHF | 207.87% |
| 2004 FY | -30.67 Million CHF | -17.72% |
| 2003 FY | -26.05 Million CHF | 46.16% |
| 2002 FY | -48.39 Million CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Relief Therapeutics Holding AG | -10.24 Million CHF | 1887.496% |
| Santhera Pharmaceuticals Holding AG | -5.3 Million CHF | 3550.057% |
| Basilea Pharmaceutica AG | 116.11 Million CHF | -57.711% |
| Bachem Holding AG | -157.32 Million CHF | 216.402% |
| Siegfried Holding AG | 468.63 Million CHF | 60.923% |
| Molecular Partners AG | -183.23 Million CHF | 199.941% |